Role of the vascular endothelium and plaque in acute ischemic stroke

Jane A. Madden, PhD

ABSTRACT

The underlying cause of stroke lies in the damage to the arterial endothelial cell layer. The most profound damage is due to atherosclerosis, which can either occlude an artery or produce a thromboembolism. Diabetes and inflammation contribute to atherosclerosis and the associated endothelial damage by initiating and promoting the deposition of modified lipids in the subendothelium and by inhibiting endothelial nitric oxide (NO) production. At the same time, both production of endothelin-1 and generation of reactive oxygen species increase. In addition, leukocytes adhere to the endothelium and levels of C-reactive protein increase. The stroke that ensues upon cerebral artery occlusion or plaque rupture continues and exacerbates endothelial damage. Statins have been shown to be helpful in preventing stroke and diminishing its consequences. An international clinical trial to determine if an NO donor is effective (Efficacy of Nitric Oxide in Stroke study) is currently under way. Other interventions such as antioxidants, p kinase inhibition, and endothelial progenitor cells offer promising avenues of research and perhaps therapeutic avenues for treatment of stroke. This article discusses the role of the vascular endothelium in ischemic stroke and those interventions that may provide plausible avenues for future therapy.

Stroke is a heterogeneous phenomenon that arises from a multitude of disruptions, diseases, and insults to the arterial wall. The most serious consequence of these is atherosclerosis, which has become the leading cause of death in the developing world. Atherosclerosis contributes either directly to a stroke through occlusion of a cerebral artery or indirectly by the production of a distal thromboembolism. The list of risk factors for both atherosclerosis and stroke reads like a litany of modern society’s ills: smoking, obesity, hypertension, diabetes, and inflammation arising from systemic diseases or recurrent infections. This article summarizes the roles of atherosclerosis and the vascular endothelium in cerebral ischemia.

ATHEROSCLEROSIS

Atherosclerosis is a progressive deposition of modified lipids in the subendothelial layers. During the process, macrophages oxidize and phagocytose low-density lipoproteins to form lipid peroxides, thereby upregulating adhesion molecules. Cholesterol esters accumulate and foam cells form, processes which lead to further deterioration of endothelial cell function. Once the endothelium is physically or metabolically impaired, arterial smooth muscle cells proliferate, leading to further narrowing of the vessel lumen. Mast cells release metalloproteinases and elastase, both of which contribute to eventual plaque rupture and stroke (figure).

ENDOTHELIUM

The endothelium, the single layer of cells on the luminal surface of an artery, is a metabolically active interface between blood and tissue that modulates blood flow and nutrient delivery as well as regulating blood coagulation and thrombosis. The endothelium is also responsible for synthesis of the major vasodilators nitric oxide (NO), prostaglandins, and endothelium-derived hyperpolarizing factor (EDHF). It also

GLOSSARY

BMSCs = bone marrow stromal cells; CRP = C-reactive protein; EDHF = endothelium-derived hyperpolarizing factor; eNOS = endothelial nitric oxide synthase; EPC = endothelial progenitor cell; ET = endothelin; HT = hemorrhagic transformation; MMPs = matrix metalloproteases; NO = nitric oxide; RAAS = renin-angiotensin-aldosterone system; ROS = reactive oxygen species.
synthesizes the powerful vasoconstrictors endothelin (ET) and angiotensin II. In addition, the endothelium is a rich source of reactive oxygen species (ROS), which are known for triggering as well as being produced by inflammation.

NO, which is synthesized from L-arginine by the enzyme eNOS (endothelial NO synthase), is important not only for its vasodilator effects but also for its role in the inhibition of smooth muscle cell growth and proliferation, limiting of inflammation, and reduction of platelet aggregation. NO protects against ischemic stroke by increasing collateral flow to ischemic areas of the brain.5 Damage to the endothelium—which gross denudation, disturbances in shear stresses, or the formation of atherosclerotic plaque—significantly impairs the dilatory and inhibitory functions.

**FACTORS PREDISPOSING TO ATHEROSCLEROSIS AND STROKE** Renin-angiotensin-aldosterone system. Activation of the renin-angiotensin-aldosterone system (RAAS) and the resultant elevations in angiotensin II and aldosterone contribute to altered insulin/insulin-like growth factor-1 signaling pathways, insulin resistance, and ROS formation. This cascade impairs endothelium-mediated vasodilation and leads to angiotensin II–mediated vasoconstriction and hypertension, as well as pathologic growth and remodeling of the vasculature.6 One of the mechanisms that underlies aldosterone-dependent remodeling may involve the upregulation of a family of zinc-dependent proteases known as matrix metalloproteases (MMPs).7 MMPs are primary proteolytic enzymes that turn over the vascular extracellular matrix by attacking type IV collagen, laminin, and fibronectin, components of the basal lamina around cerebral blood vessels.8

**Diabetes.** Both prediabetes and diabetes impair NO-mediated vasodilation, even before atheroma formation.4 Activation of eNOS is blocked, and there is increased endothelial cell production of ROS, especially superoxide. Superoxide further reduces the vasodilator effects of NO. A reaction between NO and the ROS yields peroxynitrite, which uncouples eNOS by oxidizing the NO synthesis cofactor tetrahydrobiopterin, resulting in the production of \( \text{O}_2 \) by eNOS.9 This blunted eNOS expression and resulting reduction in NO production become a vicious circle10: atherosclerotic lesions form or progress in size, platelets interact directly on intact endothelial cells, and the number of endothelial progenitor cells (EPCs) decreases, all resulting in an even greater deficiency of eNOS. An excess of free fatty acids, pro-
duced as a consequence of diabetes, exacerbates endothelial damage. These fatty acids activate protein kinase C, inhibit phosphatidylinositol-3 kinase (an eNOS agonist pathway), and increase ROS. The end result is that not only does NO production decrease, but what little NO is produced becomes less available. The formation of peroxynitrite by the reaction of NO and ROS also decreases the synthesis of the other prominent vasodilator, prostacyclin.

The increased activation of both endothelial and vascular cell nuclear factor κB and activator protein regulates the expression of genes that participate in atherogenic processes. Leukocyte-cell adhesion molecules form on the endothelium, and leukocyte-attracting chemokines are produced. Ultimately, production of the potent vasoconstrictors ET-1 and angiotensin II, along with vasoconstrictor prostanoids, reduces the arterial lumen and leads to even greater complications in a lumen already constricted with arterial plaque.

**Inflammation.** Acute or chronic inflammation occurs throughout life. Every infection—respiratory, urinary tract, dental—either acute or chronic, can cause development or exacerbation of atherosclerosis. The steady and progressive damage due to inflammatory events accumulates over time, and when inflammation and infection interact with genetic predisposition and traditional risk factors, the risk of stroke may be enhanced.

As mentioned earlier, there is a strong association between inflammation and vascular risk factors such as diabetes, smoking, hypertension, and hyperlipidemia, and the inflammatory indexes such as leukocyte count, C-reactive protein (CRP), and fibrinogen.

Inflammatory damage to the vasculature is mediated by complex mechanisms. Briefly, inflammatory cells such as macrophages and T-lymphocytes deposit in the subendothelial cell layer and cause release of inflammatory mediators or growth factors, including interleukins, tumor necrosis factor α, interferons, transforming growth factor β, and CRP. In addition, monocyte chemotactic protein-1 and macrophage protein 1α are released from glial cells and bind to the endothelium. Intracellular adhesion molecule-1, E-selectin, tissue factor, and plasminogen activator inhibitor-1 are upregulated to facilitate leukocyte adherence. Thrombomodulin and tissue plasminogen activator are downregulated.

Elevated levels of CRP, a biomarker of inflammation, are correlated with cardiovascular disease risk and endothelial cell dysfunction, including von Willebrand factor and collagen, are exposed. Platelets then adhere to these proteins and become activated by thromboxane A2 and secretion of platelet granules. Generation and release of soluble platelet agonists leads to platelet aggregation and the formation of an occluding thrombus. The cerebrovascular damage is early and progressive. Preexisting damage to the arterial wall due to atherosclerosis is compounded by cerebral edema and hemorrhagic transformation (HT) following the stroke. The significant increase in MMP levels after stroke may contribute to both the edema and HT.

Disruption of the blood–brain barrier, often as a result of administration of tissue plasminogen activator, can also lead to edema and HT and contribute to an additional increase in ET-1 production and decreased angiopoietin. The actin cytoskeleton of the vessel is altered and myogenic tone is impaired, leading to loss of autoregulation in the cerebral circulation. Even more damaging is the massive production of ROS, particularly superoxide. Superoxide contributes to altered responses to acetylcholine and CO2, increased platelet aggregability, further disruption of the endothelial layer, and increased blood–brain barrier permeability. There is more disruption of the endothelial cells, as well as increased peroxynitrite production. Unlike superoxide, peroxynitrite is not a free radical but a powerful oxidant that triggers inflammation and apoptosis. All of this damage is exacerbated in patients with diabetes and may be correlated with the reduced number of circulating EPCs.

Recently, a study using MRI suggested that type VI atherosclerotic plaque ruptures (cap rupture, hemorrhage, or thrombosis) in unstable patients with symptoms of TIA or stroke could help relate plaque characteristics to the acute clinical event. Further work is needed to determine whether plaque characterization by MRI will prove to be useful in the detection of presymptomatic lesions at risk of rupture.

**Can endothelial function be improved pre- or poststroke?** Considerable research efforts have been directed toward improving and repairing endothelial function both pre- and poststroke.

**Statins.** The most promising therapy certainly seems to be the statins. Statins augment NO production and produce anti-inflammatory and anti-thrombotic factors, along with immunomodulation to limit endothelial damage. Abrupt withdrawal of statins can lead to the overshoot activation of Rho...
GTPase and nicotinamide adenine dinucleotide phosphate (NADPH) oxidase complex (Rac-1), a negative regulation of eNOS expression, and decrease of NO bioavailability. Other consequences include an oxidative burst and NO scavenging by superoxide, inflammation, and thrombosis.20

The Efficacy of Nitric Oxide in Stroke clinical trial. The Efficacy of Nitric Oxide in Stroke (ENOS) study has been undertaken to determine the safety and efficacy of 1) transdermal glyceryl trinitrate (an NO donor) or a control and 2) continuing or temporarily stopping prior antihypertensive medication in patients with ischemic or hemorrhagic stroke. This clinical study is a collaborative, international, multicenter, prospective, randomized, single-blind, blinded-endpoint, parallel-group, controlled trial that since its beginning in 2003 has (as of mid-2011) enrolled over 2,300 patients worldwide.

Antioxidants and other compounds. Antioxidants administered pre- or poststroke are also another source of investigation, although most studies have been done in animals. Ginkgo biloba, superoxide dismutase, and aspirin have been investigated, with varying degrees of success.9

ET receptor antagonists, particularly for the ET_A receptor, may turn out to be useful, because blockade with S-0139 suppresses blood–brain barrier disruption and brain edema.21 Whether inhibiting ET_B receptors will be similarly useful is not yet certain, since the response may result in different results under control and disease (diabetic) conditions.16

Ivrabradine, an inhibitor of the I9(f) current in the sinoatrial node that lowers heart rate without affecting blood pressure or contractility, was effective in reducing infarct volume in mice with occluded cerebral arteries, presumably due to improved endothelium function and reduced oxidative stress.22 Whether inhibiting ET_B receptors will be similarly useful is not yet certain, since the response may result in different results under control and disease (diabetic) conditions.16

DISCUSSION

Stroke has a number of risk factors, many of which can be controlled by adherence to a healthy lifestyle. However, when the arterial endothelium is injured due to one or a combination of these risk factors, the damage is insidious, progressive, and multifactorial. Identification of therapeutic targets for existing drugs such as statins and NO, along with the development of future treatments such as α kinase inhibition, EPCs, and BMSCs, may offer hope of prevention and cure for stroke.

REFERENCES


Role of the vascular endothelium and plaque in acute ischemic stroke

Jane A. Madden

*Neurology* 2012;79:S58-S62

DOI 10.1212/WNL.0b013e3182695836

This information is current as of September 24, 2012

<table>
<thead>
<tr>
<th>Updated Information &amp; Services</th>
<th>including high resolution figures, can be found at: <a href="http://n.neurology.org/content/79/13_Supplement_1/S58.full">http://n.neurology.org/content/79/13_Supplement_1/S58.full</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>References</td>
<td>This article cites 26 articles, 17 of which you can access for free at: <a href="http://n.neurology.org/content/79/13_Supplement_1/S58.full#ref-list-1">http://n.neurology.org/content/79/13_Supplement_1/S58.full#ref-list-1</a></td>
</tr>
<tr>
<td>Subspecialty Collections</td>
<td>This article, along with others on similar topics, appears in the following collection(s): All Cerebrovascular disease/Stroke <a href="http://n.neurology.org/cgi/collection/all_cerebrovascular_disease_stroke">http://n.neurology.org/cgi/collection/all_cerebrovascular_disease_stroke</a></td>
</tr>
<tr>
<td>Permissions &amp; Licensing</td>
<td>Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: <a href="http://www.neurology.org/about/about_the_journal#permissions">http://www.neurology.org/about/about_the_journal#permissions</a></td>
</tr>
<tr>
<td>Reprints</td>
<td>Information about ordering reprints can be found online: <a href="http://n.neurology.org/subscribers/advertise">http://n.neurology.org/subscribers/advertise</a></td>
</tr>
</tbody>
</table>

*Neurology* © is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright © 2012 by AAN Enterprises, Inc. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.